Skip to main content

Table 2 Summary of neonatal M20 Tg mice injected with αS proteins a

From: Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein

Mouse strain Inoculums Age at harvest Number of mice Pathological findings
M20 (WT αS) fib αS (2 μl of 1 mg/ml) 1 month 7 No inclusions
M20 (WT αS) fib αS (2 μl of 1 mg/ml) 2 months 5 No inclusions
M20 (WT αS) fib αS (2 μl of 1 mg/ml) 4 months 3 No inclusions
M20 (WT αS) fib αS (2 μl of 1 mg/ml) 8 months 4 4 of 4 mice show sparse cortical pathology
M20 (WT αS) fib αS (5 μl of 5 mg/ml) 1 month 4 3 of 4 mice show sparse cortical pathology
M20 (WT αS) fib αS (5 μl of 5 mg/ml) 2 months 5 4 of 5 mice show sparse cortical pathology
M20 (WT αS) fib αS (5 μl of 5 mg/ml) 4 months 3 2 of 3 mice show sparse cortical pathology
M20 (WT αS) fib αS (5 μl of 5 mg/ml) 8 months 12 12 of 12 mice show abundant pathologyb
M20 (WT αS) Δ71-82 αS (2 μl of 1 mg/ml) 1 month 5 No inclusions
M20 (WT αS) Δ71-82 αS (2 μl of 1 mg/ml) 2 months 5 No inclusions
M20 (WT αS) Δ71-82 αS (2 μl of 1 mg/ml) 4 months 3 No inclusions
M20 (WT αS) Δ71-82 αS (2 μl of 1 mg/ml) 8 months 3 No inclusions
M20 (WT αS) Δ71-82 αS (5 μl of 5 mg/ml) 1 month 7 No inclusions
M20 (WT αS) Δ71-82 αS (5 μl of 5 mg/ml) 2 months 7 No inclusions
M20 (WT αS) Δ71-82 αS (5 μl of 5 mg/ml) 8 months 6 2 out of 6 mice show abundant pathologyb
  1. a M20 Tg mice were injected with 21–140 human αS fibrils (fib) or Δ71-82 human αS at the different dosages indicated and analyzed for αS pathology at 1–8 months post-injection using pSer129 and Syn506 antibodies.
  2. b See Figure 4 for a schematic neuroanatomical map showing the distribution of αS pathology.